Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

EPICOS (Polo) RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
231/223 inconclusive
    HERO-HCQ (Naggie)
          NCT04334148    		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
    		683/676 inconclusive
      Rojas-Serrano
              NCT04318015      		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
      		65/65 inconclusive
      • inconclusive 84 % decrease in symptomatic Covid-19,infection (PCR positive symptomatic or not) (PE) with a moderate degree of certainty due to some concern in risk of bias
      Barnabas RV
              NCT04328961      		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)low
      		407/422 safety concern
      • inconclusive 10 % increase in infection (PCR positive symptomatic or not) (PE) with a high degree of certainty due to low risk of bias
      • statistically significant 58 % increase in adverse events with a high degree of certainty due to low risk of bias
      BCN PEP-CoV-2-Study 1 (Mitja NEJM)
              NCT04304053      		 RCThydroxychloroquinestandard of careCOVID-19 prophylaxis (excluding children)some concern
      		1116/1198 safety concern
      • inconclusive 14 % decrease in infection (PCR positive symptomatic or not) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • statistically significant 19.3-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
      COVID PREP HCQ (2x week, Rajasingham)
              NCT04328467      		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)low
      		495/494 safety concern
      • inconclusive 26 % decrease in infection (PCR positive symptomatic or not) (PE) with a high degree of certainty due to low risk of bias
      • statistically significant 1.0-fold increase in adverse events with a high degree of certainty due to low risk of bias
      COVID-PEP-Post exposure (Boulware)
              NCT04308668      		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)low
      		414/407 safety concern
      • statistically significant 2.3-fold increase in adverse events with a high degree of certainty due to low risk of bias
      PATCH-cohort 3 PreP (Abella)
              NCT04329923      		 RCThydroxychloroquineplaceboCOVID-19 prophylaxis (excluding children)some concern
      		66/66 inconclusive
      • inconclusive 5 % decrease in infection (PCR positive symptomatic or not) (PE) with a moderate degree of certainty due to some concern in risk of bias
      4 studies excluded by filtering options (3 RCT / 1 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons